Oruka Therapeutics, Inc.
ORKA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000907654
In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 15 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.
Q1 2023 vs. Q4 2022
How the institutions holding Oruka Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 22 | 26 | +4 |
| Shares | 2.61M | 2.52M | −91.1K (−3.5%) |
| Value | $6.19M | $5.02M | −$1.17M (−18.9%) |
New holders (5)
Institutions that held Oruka Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Group One Trading, L.P. | 23,000 | $45.8K | 0.00% |
| Charles Schwab Investment Management Inc | 14,988 | $29.8K | 0.00% |
| HRT Financial LP | 14,408 | $28.0K | 0.00% |
| Morgan Stanley | 300 | $597 | 0.00% |
| Barclays PLC | 49 | $98 | 0.00% |
Sold out (1)
Institutions that held Oruka Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Jane Street Group, LLC | 14,578 | $34.5K |